Icecure Medical is trading 5.36% up at $2.06 as U.S. equities, technology stocks, and cryptocurrency rally on falling oil prices and lower Treasury yields.
- No new company-specific announcement was identified for September 21, 2026.
- The latest major catalyst was September 10 China NMPA approval for ProSense.
- The approval enables marketing in China but predates todayβs move.